drugset / Trial / NCT00653445

Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg

NCT00653445

Phase 3 Completed AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare 6 weeks of treatment with rosuvastatin alone compared with 6 weeks of treatment of rosuvastatin combined with ezetimibe in achieving low density lipoprotein level goals.

Timeline

Start
2004-06
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Background Rosuvastatin Small molecule 40 mg